cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/00003172
title: A Randomized, Open-Label, 2-Period Crossover Study to Determine the Relative Bioavailability of TAK-491CLD Fixed-Dose Combination Tablet Compared to Coadministration of Individual TAK-491 and Chlorthalidone Tablets in Healthy Adult Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002759
title: An Open-Label, Randomized, 2-Cohort, 2-Period Crossover Study to Evaluate the Relative Bioavailability of Two TAK-491CLD Fixed-Dose Combination Tablets Compared to Individual TAK-491 and Chlorthalidone Tablets in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.15468/dl.r8vnfv
title: Occurrence Download

description: A dataset containing 420 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 "TaxonKey is one of (Stauntonia coriacea (Diels) Christenh.)"
 ]
}

 The dataset includes 420 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002316-241125135418005/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/00002758
title: A Randomized, Open-Label, 2-Period Crossover, Parallel Group Study to Determine the Effect of Food on the Pharmacokinetics of Scaled-up Fixed-Dose Combination Formulation of TAK-491 and Chlorthalidone in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002757
title: A Randomized, Open-Label, 2-Period Crossover Study to Determine the Relative Bioavailability of the TAK-491CLD High-Dose Formulation of Fixed-Dose Combination Tablets Compared to Coadministration of Individual TAK-491 and Chlorthalidone Tablets in Healthy Adult Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002756
title: An Open-Label, Randomized, 3-Period Crossover Study to Evaluate the Relative Bioavailability of TAK-491 and Chlorthalidone in Fixed-Dose Combination Following Oral Administration to Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002755
title: A Randomized, Open-Label, 3-Period Crossover Study to Evaluate the Relative Bioavailability of TAK-491 and Amlodipine in Fixed-Dose Combination Following Oral Administration to Healthy Adult Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002753
title: A Randomized, Open-Label, 2-Period Crossover Study in Healthy Adult Subjects to Determine the Relative Bioavailability of TAK-491 Granules for Reconstitution Compared to TAK-491 Tablets

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002751
title: The Effect of Antacid on the Pharmacokinetic Profile of TAK-491

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002750
title: A Phase 1, Multiple-Dose, Open-Label, Randomized, 3-Period Crossover Study to Evaluate the Effect of TAK-536 Formed From TAK-491 on the Pharmacokinetics of Digoxin in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002940
title: An Open-Label, Parallel-Group Comparison Study of Single-Dose Pharmacokinetics of TAK-491 in Subjects With Varying Degrees of Renal Impairment and Their Healthy Matched Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002748
title: Open-Label Evaluation of the Single-Dose and Multiple-Dose Pharmacokinetics of TAK-491 in Subjects With and Without Hepatic Impairment

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002746
title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of the Safety, Tolerability and Pharmacokinetics of 80 mg and 160 mg of TAK-491 in Healthy Male Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00003286
title: An Open-Label 4-Group, Parallel Design Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of TAK-438 and Its Metabolites Following a Single Oral Dose of TAK-438

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00003251
title: A Randomized, Open-Label, 2x2 Crossover Study Stratified by Gender to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of TAK-438 Administered With and Without Food in Healthy Non-Japanese Male and Non-Japanese Female Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.6084/m9.figshare.27909046
title: Supplementary Table 2 â€“ Modelling individual variation in human walking gait across populations and walking conditions via gait recognition

description: Additional details of the convolutional long short-term memory (LSTM) neural network architectures applied for gait recognition. N = number of samples.
DOI: 10.25934/00003177
title: A Phase 3, Open-Label, 4 × 4 Crossover Study to Evaluate the Pharmacokinetic Drug-Drug Interaction of the Triple Therapy with TAK-438, Amoxicillin and Clarithromycin, or with TAK-438, Amoxicillin and Metronidazole in Healthy Japanese Male Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.6084/m9.figshare.27909049
title: Supplementary Table 4 â€“ Modelling individual variation in human walking gait across populations and walking conditions via gait recognition

description: Additional details of the transformer neural network architectures. N = number of samples. Transformer encoder layer hyper-parameter settings: d_model = 6, nhead = 3, activation = 'gelu', and dim_feedforward = 1200.
DOI: 10.6084/m9.figshare.27909049.v1
title: Supplementary Table 4 â€“ Modelling individual variation in human walking gait across populations and walking conditions via gait recognition

description: Additional details of the transformer neural network architectures. N = number of samples. Transformer encoder layer hyper-parameter settings: d_model = 6, nhead = 3, activation = 'gelu', and dim_feedforward = 1200.
DOI: 10.6084/m9.figshare.27909055
title: Supplementary Table 3 â€“ Modelling individual variation in human walking gait across populations and walking conditions via gait recognition

description: Additional details of the convolutional transformer neural network architectures applied for gait recognition. N = number of samples. Transformer encoder layer hyper-parameter settings: d_model = number of input features (varied), nhead = 4, activation = 'gelu', and dim_feedforward = number of output features (varied).
DOI: 10.6084/m9.figshare.27909055.v1
title: Supplementary Table 3 â€“ Modelling individual variation in human walking gait across populations and walking conditions via gait recognition

description: Additional details of the convolutional transformer neural network architectures applied for gait recognition. N = number of samples. Transformer encoder layer hyper-parameter settings: d_model = number of input features (varied), nhead = 4, activation = 'gelu', and dim_feedforward = number of output features (varied).
DOI: 10.6084/m9.figshare.27909058
title: Supplementary Table 1 â€“ Modelling individual variation in human walking gait across populations and walking conditions via gait recognition

description: Additional details of the fully-connected and convolutional neural network architectures applied for gait recognition. N = number of samples.
DOI: 10.6084/m9.figshare.27909058.v1
title: Supplementary Table 1 â€“ Modelling individual variation in human walking gait across populations and walking conditions via gait recognition

description: Additional details of the fully-connected and convolutional neural network architectures applied for gait recognition. N = number of samples.
DOI: 10.25934/00003174
title: A Phase 2, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-438 (5, 10, 20, and 40 mg Once Daily) and AG-1749 (30 mg Once Daily) in Subjects with Erosive Esophagitis

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002743
title: A Phase 1, Single-Center, Randomized, Open-Label, 2-Period Crossover, Single-Dose Study to Evaluate the Pharmacodynamics and Pharmacokinetics of Dexlansoprazole 60 mg Capsules and Esomeprazole 40 mg Capsules in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002741
title: A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Crossover Study to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed Release Capsules 30 mg Encapsulated at Osaka with Granules Manufactured by TIL and Osaka Relative to Reference Dexlansoprazole Delayed Release Capsules 30 mg Encapsulated at Osaka With Granules Manufactured by Osaka in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002742
title: A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Crossover Study to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed Release Capsules 60 mg Encapsulated at Osaka With Granules Manufactured by TIL and Osaka Relative to Reference Dexlansoprazole Delayed Release Capsules 60 mg Encapsulated at Osaka With Granules Manufactured by Osaka in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002740
title: A Phase I, Randomized, Double-Blind, AG-1749 Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-390MR in Healthy Male Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002739
title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of the Safety, Tolerability and Pharmacokinetics of TAK-390MR in Healthy Male Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002738
title: Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis – A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00003282
title: A Phase 1, Randomized, Open-Label, Single Center, Single-Dose, 4-Period, Crossover Study to Assess the Bioavailability of 30 mg Dexlansoprazole Delayed-Release Orally Disintegrating Tablets Mixed With Water and Administered Orally Via Syringe or Via Nasogastric Tube, or Swallowed Intact With Water, Relative to Administration on the Tongue Without Water in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00003283
title: A Phase 1, Randomized, Open-Label, Single-Center, Multiple-Dose, Two- Period, Crossover Study to Assess the Pharmacodynamics and Bioavailability of 30 mg Dexlansoprazole Delayed-Release Orally Disintegrating Tablets Administered on the Tongue Relative to Oral Administration of 30 mg Dexlansoprazole Delayed-Release Capsules in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00003284
title: A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, 3-Period, Crossover Study to Assess the Effect of Food on the Bioavailability of Dexlansoprazole 30 mg Delayed-Release Orally Disintegrating Tablets Administered on the Tongue, and to Assess the Bioavailability of Dexlansoprazole 30 mg Delayed-Release Orally Disintegrating Tablets When Administered on the Tongue With Water Relative to Administration on the Tongue Without Water in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00003281
title: A Phase 1, Randomized, Open-Label, Single Center, Single Dose, Four Period, Crossover Study to Assess the Bioavailability of Three 30 mg Dexlansoprazole Delayed Release Orally Disintegrating Tablet Formulations Relative to Dexlansoprazole Delayed Release Capsule (30 mg) in Healthy Subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.